Chromocell Therapeutics Corporation (CHRO)
NYSEAMERICAN: CHRO · IEX Real-Time Price · USD
1.270
+0.020 (1.60%)
Jul 2, 2024, 3:30 PM EDT - Market closed
Chromocell Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
7.32M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 0 | - | - |
| Dec 31, 2020 | 199.93K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCHRO News
- 7 weeks ago - Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024 - GlobeNewsWire
- 3 months ago - Chromocell Issues Letter to Stockholders from Chief Executive Officer - GlobeNewsWire
- 3 months ago - Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler - GlobeNewsWire
- 3 months ago - Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023 - GlobeNewsWire
- 4 months ago - Chromocell to Present at Sidoti Virtual Investor Conference March 13-14 - GlobeNewsWire
- 4 months ago - Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions - GlobeNewsWire
- 4 months ago - Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million - GlobeNewsWire
- 4 months ago - Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering - GlobeNewsWire